Population
112 patients with solid tumors or malignant lymphoma who had undergone active chemotherapy in the last two…
Design
Cohort
Authors
Loading...
Supports Khorana stratification in chemotherapy patients; leaves open whether prophylaxis improves outcomes in high-risk groups.
The Khorana clinical model accurately predicts VTE risk and overall mortality in cancer patients undergoing active chemotherapy, identifying high-risk patients who may benefit from primary prophylaxis.
Kearney et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: